|1.||Thiemermann, Christoph: 4 articles (01/2007 - 12/2004)|
|2.||Collin, Marika: 4 articles (01/2007 - 12/2004)|
|3.||Kopelovich, Levy: 3 articles (01/2013 - 03/2012)|
|4.||Linnebacher, Michael: 2 articles (11/2013 - 01/2013)|
|5.||Hinz, Burkhard: 2 articles (11/2013 - 01/2013)|
|6.||Ramer, Robert: 2 articles (11/2013 - 01/2013)|
|7.||Wang, Hao: 2 articles (01/2013 - 11/2011)|
|8.||Ye, Ping: 2 articles (01/2013 - 11/2011)|
|9.||Mogi, Masaki: 2 articles (01/2012 - 08/2010)|
|10.||Iwanami, Jun: 2 articles (01/2012 - 08/2010)|
|1.||Vascular System Injuries
07/08/2011 - "Coadministration of GW9662 with telmisartan abolished the above mentioned greater protective effects of telmisartan against vascular injury than losartan in db/db mice. "
07/08/2011 - "We compared the effects of telmisartan, telmisartan combined with GW9662 (a PPARγ antagonist), and losartan with no PPARγ activity on vascular injury in obese type 2 diabetic db/db mice. "
06/15/2012 - "To test whether telmisartan ameliorates vascular injury in the chronic kidney disease model rat through the PPAR-γ pathway, telmisartan (5 mg/kg per day, orally), losartan (5 mg/kg per day, orally) or telmisartan plus PPAR-γ antagonist, GW9662 (1 mg/kg/day, i.p.), was administered for 14 days to subtotal nephrectomized rats (Nx). "
06/01/2015 - "TS significantly suppressed the TLR4 mediated inflammatory response by PPARγ and SARM protein activation and the effect was reversed significantly by selective PPARγ antagonist GW9662, confirming the existence of link between PPARγ activation and TLR4 mediated inflammation via SARM. "
06/15/2012 - "Cotreatment with GW9662 partly blunted the normalization of vascular dysfunction and inflammation. "
10/01/2012 - "Increased apoptosis and inflammation was also observed after treatment with the PPARγ antagonist GW9662. "
10/01/2010 - "GW9662 significantly antagonized the effect of the rosiglitazone and abolished the protective effect against SCI. Taken together, our results clearly demonstrate that administration of rosiglitazone after SCI reduces the development of inflammation and tissue injury associated with spinal cord trauma."
01/01/2012 - "Moreover, we observed that administration of C21 enhanced adipocyte differentiation and PPARγ DNA-binding activity, with a decrease in inflammation in white adipose tissue, whereas these effects of C21 were attenuated by co-treatment with GW9662. "
01/01/2007 - "Ki16425, but not GW9662, attenuated the beneficial effects of LPA 18:0, however, Ki16425 and GW9662 attenuated the beneficial effects of 18:1. In conclusion, LPA reduces the organ injury caused by endotoxemia in the rat. "
04/01/2006 - "Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia."
04/01/2006 - "Rats were pretreated with low-dose lipopolysaccharide (1 mg/kg intraperitoneally, 24 hrs before induction of endotoxemia) in the absence or presence of the selective PPAR-gamma antagonists GW9662 (1 mg/kg intraperitoneally) or T0070907 (1 mg/kg intraperitoneally) or the selective cyclooxygenase-2 inhibitor parecoxib (20 mg/kg intraperitoneally). "
12/01/2013 - "Paeoniflorin attenuated TNFα-mediated suppression of the expressions of PPARγ and PPARγ target genes, and the improvement of paeoniflorin on TNFα-induced insulin resistance was attenuated by GW9662, an antagonist of PPARγ activity. "
10/01/2010 - "Furthermore, pretreatment of peroxisome proliferator-activated receptor γ (PPARγ) antagonist, GW9662 not only reversed indomethacin-modified COX-2 and iNOS levels but also reversed indomethacin-improved insulin sensitivity determined by homeostasis model assessment-insulin resistance (HOMA-IR). "
05/24/2013 - "The results displayed pioglitazone improved the mechanical hyperalgesia, and attenuated the astrocyte and NF-κB activation and the inflammatory cytokine upregulation in nerve-injured rats, which might be reversed by GW9662. "
11/01/2008 - "Administration of pioglitazone for the first week after PSL attenuated thermal hyperalgesia and tactile allodynia, which was dose-dependent and blocked by GW9662 (2 mg/kg, i.p.), a PPARgamma antagonist. "
|4.||Peroxisome Proliferator-Activated Receptors (PPAR)
|1.||Heterologous Transplantation (Xenotransplantation)